Novartis India Pvt. Ltd. is a multinational pharmaceutical company having global headquarters in Basel, Switzerland, and Indian headquarters in Mumbai. In 1996, Ciba-Geigy's pharmaceutical and agrochemical division merged with the same divisions of Sandoz and formed a company Novartis, the independent entity. It is one of the largest pharmaceutical companies by both sales and market capitalization. The company concentrates on the evolving needs of patients and advanced medications. With a mission to discover new ways to enhance and extend people's lives, the team of Novartis is on the way continues improvements. Novartis Global Drug Development (GDD) delivers successful innovations to improve patients’ lives.

Novartis manufactures drugs terbinafine (Lamisil), clozapine (Clozaril), methylphenidate (Ritalin), diclofenac (Voltaren), letrozole (Femara), carbamazepine (Tegretol), ciclosporin (Neoral/Sandimmun), imatinib mesylate (Gleevec/Glivec), valsartan (Diovan),  and others. Novartis is a full member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). Novartis started an Arogya Parivar social business initiative that brings health education and affordable medicines to rural pockets in 1996. Novartis is constantly working in the direction to control and eliminate diseases like malaria and leprosy. 

Novartis and its predecessor companies, Ciba-Geigy and Sandoz trace roots back more than 250 years, with a rich history of developing innovative pharmaceutical and healthcare products. The company initially started with the production of synthetic fabric dyes, went towards the production of chemicals and ultimately started the manufacturing of pharmaceuticals.  In 2002, Novartis unifies and strengthens its global research network by creating the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, USA. Novartis completes a series of transactions that focus the company on three divisions that is Alcon (eye care), Pharmaceuticals and Sandoz (generic medicines).